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Background: Citicoline is one of the neuroprotective agents that have been used as a therapy in stroke patients.
There is limited published data describing the mechanisms through which it acts.
Methods: We used in vitro angiogenesis assays: migration, proliferation, differentiation into tube-like structures in
Matrigel™ and spheroid development assays in human brain microvessel endothelial cells (hCMEC/D3). Western
blotting was performed on protein extraction from hCMEC/D3 stimulated with citicoline. An analysis of citicoline
signalling pathways was previously studied using a Kinexus phospho-protein screening array. A staurosporin/
calcium ionophore-induced apoptosis assay was performed by seeding hCMEC/D3 on to glass coverslips in serum
poor medium. In a pilot in vivo study, transient MCAO in rats was carried out with and without citicoline treatment
(1000 mg/Kg) applied at the time of occlusion and subsequently every 3 days until euthanasia (21 days). Vascularity
of the stroke-affected regions was examined by immunohistochemistry.
Results: Citicoline presented no mitogenic and chemotactic effects on hCMEC/D3; however, it significantly
increased wound recovery, the formation of tube-like structures in Matrigel™ and enhanced spheroid development
and sprouting. Citicoline induced the expression of phospho-extracellular-signal regulated kinase (ERK)-1/2. Kinexus
assays showed an over-expression of insulin receptor substrate-1 (IRS-1). Knock-down of IRS-1 with targeted siRNA
in our hCMEC/D3 inhibited the pro-angiogenic effects of citicoline. The percentage of surviving cells was higher in
the presence of citicoline. Citicoline treatment significantly increased the numbers of new, active CD105-positive
microvessels following MCAO.
Conclusions: The findings demonstrate both a pro-angiogenic and protective effect of citicoline on hCMEC/D3
in vitro and following middle cerebral artery occlusion (MCAO) in vivo.
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Citicoline, is an essential component of cell membrane
phospholipids, and is one of the neuroprotective agents
that have been used as a therapy in stroke patients. It has
been extensively tested in many stroke studies and has
shown promising results with regard to the reduction of
infarct size and improvement of functional recovery. Citi-
coline (CDP-choline or cytidinediphosphate choline; cyti-
dine 50-diphosphocholine) is a complex organic molecule
composed of ribose, pyrophosphate, cytosine and choline
[1]. Citicoline has been suggested to provide beneficial re-
covery and neuroprotective effects in brain traumatic in-
juries, stroke, brain ageing and neurodegenerative diseases
[2,3], although the exact mechanisms through which it
operates are not fully understood.
The most recent clinical and pre-clinical updates have
been published by Davalos and Secades [4]. In this article,
they provide information on basic research studies using
animal models, where individual studies have demon-
strated for example, increased protection against cognitive
impairment in chronic hypoperfused rats [5], as well as a
meta-analysis of the effects of citicoline using a systematic
review of all the data collected (15 studies on focal ischae-
mia using the rat model). Here, Giralt et al. [6] showed
overall a reduced infarct volume of 30% (transient occlu-
sion) and 25% (permanent occlusion), however disap-
pointingly, there was no improvement in neurological
outcome. Finally, Saver et al., [7] performed a meta-
analysis using 10 trials of ischaemic/haemorrhagic stroke
where the patients were treated with citicoline. Results
showed that citicoline treatment was associated with a sig-
nificant reduction in the frequency of death and disability
at long-term follow up with no adverse affects. In all
instances, citicoline was administered within 24 h of the
stroke occurrence. Interestingly, ‘priming’ of patients with
citicoline following transient ischaemic attack (TIA) or
minor stroke has not been considered as yet and also,
since the mechanism of its action is not fully elucidated,
optimal application cannot be determined accurately.
In terms of analysis of the signalling mechanisms asso-
ciated with citicoline-induced protection, Krupinski
et al., [8] showed that citicoline treated animals showed
a dramatic reduction in immunoreactive cells for pro-
caspases 1, 2, 3, 6 and 8 in the ischemic infarction area
when compared with the control group. The number of
cells expressing cleaved caspase-3 and nuclear DNA
fragmentation in the penumbra area was significantly
reduced in animals treated with citicoline. The data sug-
gests that citicoline may protect the ischemic neurons
by providing a negative effect on the activation of the
caspase apoptotic pathway.
As far as we are aware, no-one has examined the pos-
sible beneficial effects of citicoline treatment on revascu-
larization and angiogenesis after stroke. Our preliminaryin vitro studies have shown that citicoline also protects
human brain microvascular endothelial cells (hCMEC/
D3) against apoptosis and excitotoxic damage, strongly
induces angiogenesis and significantly increases vascular-
isation in stroke affected regions of rats following
MCAO through a signalling pathway involving activa-
tion of the insulin-receptor-substrate-1 (IRS-1), suggest-
ing a novel protective mechanism of action and
potential clinical application for improvement of tissue
reperfusion and neuronal survival after ischaemic stroke.
Methods
Cell culture
Human brain micro-vessel endothelial cell (EC) line
named hCMEC/D3 was grown in endothelial basal
medium-2 (EBM-2) medium supplemented with growth
factors and hydrocortisone as described previously [9].
Cells were seeded into T25 flasks pre-coated with 0.1%
collagen and maintained in a humidified 5% CO2 atmos-
phere at 37°C. Every three days reaching the confluence,
the cells were detached under the enzymatic activity of
the trypsin then the cells in suspension were centrifuged
for 5 min at 1300 rpm then seeded into new pre-coated
T25 flasks. Throughout the study, the cells used were be-
tween passages 28 and 38. Cells were routinely cultured as
described in our previously published work [10].
Staurosporin/ionophore-induced apoptosis assay
In this assay, glass coverslips were sterilized in a bath of
100% ethanol for 10–20 min then left to air dry. The cov-
erslips were put in a 24-well plate and pre-coated with
500 μl of 0.1% collagen in acetic acid and then incubated
for 1 h. hCMEC/D3 were cultured in complete medium
at a concentration of 5 × 104 cells/ml on collagen pre-
coated coverslips for 4 h-incubation. Then, the medium
was replaced with serum-free medium and the cells were
incubated. After 24 h incubation, the cells were pre-
incubated with 10 μM citicoline for 4 h prior to apoptosis
induction. After the pre-incubation with citicoline, apop-
tosis was induced using calcium ionophore (10 μM/
24 h); or staurosporin: 10 μM/4 h (concentrations deter-
mined from pilot studies as optimal) or by exposure to
oxygen-deprivation (12 h, 1% O2; hypoxia confirmed by
up-regulation of HIF-1α as determined in our pilot stud-
ies). These concentrations have previously been shown to
induce apoptosis in about 40-90% of the cell population.
For staining, one hour before the termination of the ex-
periment, propidium iodide (PI; 10 μg/ml) was added in
each well as an indicator of DNA damage. After 1 h, the
medium was discarded and the cells were washed with
PBS then fixed with 4% paraformaldehyde for 20 min at
room temperature. Subsequently, cells were washed three
times with PBS and exposed to 1 μg/ml Hoechst 6024
stain solution diluted in PBS at room temperature for
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and one drop of FluorSave™ reagent was added on
frosted glass slides and the coverslips were put upside
down on the drops. An average of six fields at x200 of
magnification was photographed per coverslip using an
Axivoert fluorescence microscope. The apoptotic index
is expressed as the number of apoptotic cells relative to
the total number of cells (% apoptotic cells). In this ex-
periment, triplicate wells were run for each condition
with controls consisting of untreated cells.
Angiogenesis assays: cell proliferation
hCMEC/D3 cells were seeded at a concentration of 8 ×
104 cells/ml in 500 μl of complete basal medium in each
well of 24-well plate. After 4 h, the medium was changed
to serum-poor medium (SPM) containing 1% FBS con-
taining different concentrations of citicoline (1 μM,
10 μM and 100 μM; NOTE; pilot experiments were car-
ried out using 1-100 μM citicoline and optimized for the
use of 10 μM subsequently as this produced the most
prominent responses). After 72 h incubation, cells were
washed with PBS and detached with trypsin. Cells were
counted in a Coulter counter at least three times for each
well. In this experiment, cells were treated in triplicate for
each experimental condition. Cell migration (Boyden
Chamber: chemotaxis assay)- Inserts of Transwell CostarW
porous membranes were coated with 0.1% collagen and
left for air dry in a 24-well plate. (Wound recovery)-cells
were seeded onto plastic coverslips and when confluent,
were scraped with a razor to induce straight lesions.
Cells were seeded in 100 μL of serum- poor medium
containing 1% FBS at a concentration of 7.3 × 104 cells/
ml. The inserts containing hCMEC/D3 were placed in a
24-well plate containing 500 μl of serum poor medium
containing 1% FBS and supplemented with either citico-
line (10 μM/ml) or FGF-2 (25 ng/ml), used as a posi-
tive control. Cells were treated in triplicate for each
experimental condition. (Boyden chamber)-After 24 h
incubation, the medium was removed from the insert
and the cells which had migrated through the pores to
the bottom side of the insert were fixed with 4% paraf-
ormaldahyde. Cotton swabs were soaked with PBS and
used in order to remove the cells that did not migrate.
After fixation, the migrated cells were stained with
Giemsa (3 minutes). An optical microscope was used to
count randomly five microscopic fields from each insert.
(Wound healing)-after 24 h the plastic coverslips were
fixed in paraformaldehyde and cell migration examined
under a microscope at low power. Tube-like structure
formation in Matrigel- EC (2 × 106 cells/ml) were mixed
with equal volume of growth factor-reduced Matrigel™
containing citicoline (10 mM) or fibroblast growth
factor-2 (FGF-2) (25 ng/ml). Any material in the contact
with the gel was cold to avoid the gel polymerization. In a48-well plate, a total amount of 35 μl of this mixture was
placed in a tear-like drop in the middle of the well and
left to polymerize for 1 h incubation. Then, 0,5 ml of
complete medium was added into each well. After 24 h
incubation, 4% paraformaldahyde was added to fix the
endothelial tube-like structures embedded in the gel. Five
areas from each well were counted under optical micro-
scope. Spheroids were produced by inoculation of centri-
fuged endothelial cells into matrigel with or without
addition of citicoline or FGF-2 as a positive control and
their development including sprout formation monitored
as described above over a period of 7 days. At least 10
sprouts were measured for each condition and the experi-
ments repeated at least 3 times.
Protein extraction and western blotting
EC (3 × 105 cells/ml; 2 ml) were seeded in complete
medium in 6-well plate and incubated for 48 h. Then, the
medium was replaced with SPM containing 1% FBS. After
24 h incubation, the cells were stimulated with citicoline
at 1-10-50 μM for 10 min then the cells were immedi-
ately washed with 1 ml of PBS and gently lysed on ice in
50 μl of ice-cold homogenized lysis buffer (PH 7.2). The
cells then were scraped, the cell lysate proteins collected
and transferred into 0.5 ml micro-centrifuge tubes. Sam-
ples were sonicated four times for 10 seconds each time
with 10–15 second intervals on ice to rapture the cells
and to shear nuclear DNA. Cell lysates were centrifuged
at 20,000 g for 20 min and the protein concentration was
determined using the BioRad protein assay.
In our preliminary un-published studies, we showed
that citicoline also strongly induced angiogenesis in our
bovine aortic EC (BAEC) and for this reason we per-
formed a phospho-site protein expression screen using
Kinex™ antibodies microarray KAM1.3 and performed
by Kinexus (Bioinformatics Corporation, Vancouver,
Canada). The most relevant phospho-protein expression
up- or down-regulated by citicoline were confirmed by
Western blotting (IRS-1, HER2 and Histone H2B; see
additionally supplied data). Since phosphorylation of
IRS-1 was most apparent when translated to our
hCMEC/D3 cells, we investigated its role in intracellular
signalling in more detail here. Standard siRNA transfec-
tion (using lipofectamine) was employed to induce a
transient down-regulation of IRS-1 RNA (approximately
85-90%-data not included; Figure 1B and C). After 24 h
exposure to siRNA or scrambled sequences, cells were
used for analysis of tube-like structure formation
described previously. The experiment was repeated twice
in triplicate wells and a representative example shown.
Transient rat MCAO
Four male Wistar rats (Charles River) were used in each
group (control and citicoline treated), with a weight of
Figure 1 Effect of citicoline, hypoxia, and the Ca ionophore A23187 on cell death in hCMEC/D3. A) Shows control hCMEC/D3 without
citicoline or staurosporin treatment (i), cells treated with staurosporin (ii; 10 μM), and cells pre-incubated with citicoline for 4 h before apoptosis
was induced with 10 μM staurosporin (24 h; iii). The presence of citicoline (10 μM) was sufficient to significantly inhibit cell apoptosis (iii)
B) Shows control hCMEC/D3 without citicoline or hypoxia treatment (i), cells treated after exposure to hypoxia (ii; 12 h; 1% O2) and cells
pre-incubated with citicoline for 4 h prior to subjecting to hypoxia (iii). The data shows that citicoline (10 μM) was able to significantly reduce the
number of cells undergoing apoptosis (iii). C) Shows that citicoline protected the cells against apoptosis induced by calcium ionophore. (i) Shows
control cells, (ii) the effect of 10 μM/24 h treatment with Ca ionophore, and (iii), the effect of 4 h pre-treatment with citicoline before addition of
10 μM Ca ionophore. Citicoline significantly protected against apoptosis induced by the ionophore. The bar graphs shows data from one
representative experiment carried out in triplicate wells. All experiments were performed three times. Cells were considered apoptotic when cell
nuclei demonstrated positive PI/Hoechst staining and apoptotic morphology (Data not shown). For quantification of PI/Hoechst -positive cells,
four fields per section were examined at 200-fold magnification. The apoptotic index was calculated using the formula: Apoptotic index = 100 *
(number of PI/Hoescht + cell nuclei per field/total number of cell nuclei per field).
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kept on a 12/12 hours light/darkness cycle, with access
to food and water ad libitum.
The ischemic lesion was induced by transient (90 -
minutes) occlusion of the right middle cerebral arte-
ry (MCAO), using the intraluminal thread occlusion
method, described elsewhere [11], under isofluorane
anesthesia. The occlusion period and the successful
reperfusion of the right MCA were controlled by con-
tinuous recordings of ipsilateral laser-Doppler flowmetry
(LDF). Animals were intraperitoneally treated with ei-
ther citicoline (1000 mg/Kg) or saline. Drugs were daily
administered until day 7. The first dose was given
15 minutes before reperfusion. 21 days after occlusionanimals were anesthetized and perfused through the heart
with heparinized saline, followed by 4% paraformaldehyde.
Brains were cryoprotected with 30% sucrose, frozen at
−40°C and 8-μm thick coronal sections were cut in a cryo-
stat. 1, 7 and 21 days after occlusion rats were anesthe-
tized and MRI T2-weighted images were acquired at 7 T
(Bruker BioSpin), in order to study evolution of lesion vol-
ume. There was no mortality in this experimental group.
Procedures followed were in accordance with institutional
guidelines.
Immunohistochemistry
Immunohistochemical staining was used to determine the
relative numbers of microvessels (anti-CD31) and active
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stroked brain tissue after 21 days (n = 5). The mean num-
ber of vessels from five areas of stroke-affected tissue was
counted microscopically (× 20) in eight sections per
animal. Double immunofluorescence was used to assess
the distribution of the phospho-protein IRS-1 in rela-
tion to active microvessels in the stroke region (CD105/
endoglin mouse monoclonal antibody). After incubation
with primary antibodies for 1 h at room temperature
(1:100), sections were washed and then incubated with
the appropriate secondary antibodies (1:50) − fluorescein
isothiocyanate-conjugated sheep anti-mouse IgG (Jackson)
or tetramethylrhodamineisothiocyanate-conjugated rabbit
anti-goat (Jackson). Images were captured with Nikon
80i Digital Microscope using Nis Elements 3.21 software
with multichannel capture option. Negative control
slides were included where the primary antibody was
replaced with PBS.
Statistical analysis
All in vitro experiments were performed at least three
times and the results are expressed as the means ± S.D.
Section analysis by immunohistochemistry involved
counting the numbers of microvessels from 5 regions
within the infarcted tissue and from 3 separate sections
(1, 5, and 10 from serial sections) for each condition.
Statistical significance was tested by Student’s t-test and
data were considered significant when p ≤ 0.05.
Results
Citicoline protects hCMEC/D3 against cell damage/
apoptosis
EC were pre-incubated with 10 μM citicoline for 4 h.
Then, the cells were incubated with 1-10 μM stauros-
porin in DMSO for 4 h and 24 h, respectively. These
concentrations were chosen in order to identify appro-
priate levels of cell damage/apoptosis and were classi-
fied as preliminary studies. In these experiments, the
numbers of apoptotic cells were approximately 40%
and 60% at 10 μM (4 h and 24 h respectively) (data
not shown). Therefore, 10 μM/4 h was the chosen
treatment in order to evaluate whether citicoline could
protect the cells against cell death pathways. Pre-
treatment of hCMEC/D3 cells with citicoline signifi-
cantly decreased the number of damaged/apoptotic
cells, determined by counting the numbers of PI-
positive nuclei at the end of the experiment, under
these conditions (Figure 1A; P < 0.05). Since hypoxia is
a key feature of acute ischaemic stroke and a major
activator of cell apoptotic pathways, we examined its
effect on our EC in the presence of citicoline (10 μM/
4 h pre-incubation). Again, the presence of citicoline
in the media significantly protected the cells against
apoptosis/cell damage (Figure 1B; p < 0.05). Increasedexpression of and release of Ca2+ Kainic acid and glu-
tamate also leads to increased cell death after stroke.
Ionophore treatment of EC is known to induce Ca in-
flux and rapid dephosphorylation of eNOS at Thr495
resulting in eNOS activation. For this reason, we
exposed our EC to the Ca ionophore A23187 (10 μM/
24 h), after pre-treatment with citicoline. Figure 1C
shows that the Ca ionophore caused significant reduc-
tion in survival of cells after 24 h. However in the
presence of citicoline, the effects were reversed and
the cells remained attached and morphologically iden-
tical to control-untreated cells (p < 0.05). The possible
mechanism through which citicoline provides this pro-
tection is discussed later in this results section.
Citicoline had no mitogenic or chemotactic effect but
significantly increased wound recovery, spheroid sprouting
and strongly induced endothelial tube-like structure
formation in Matrigel
Addition of 10 μM citicoline to hCMEC/D3 had no ef-
fect on cell proliferation after 72 h incubation com-
pared with control-untreated cells (data not included).
The chemotactic effect of citicoline was measured using
the Boyden chamber assay. EC were stimulated with
10 μM citicoline and FGF-2 was used as the positive
control. After 24 h incubation, a significant increase of
cell migration across the filters induced by FGF-2 was
observed whereas citicoline showed no chemotactic ef-
fect on the EC, compared to the control (data not
included).
However, a significant increase in the wound healing
response was seen in hCMEC/D3 after treatment with
citicoline (numbers of cells migrated beyond the scratch
wound and distance migrated); 10 μM; Figure 2A;
(p < 0.05). Similarly, addition of citicoline (10 μM)
significantly increased the formation and intensity of
spheroids as well as migration of cells outwards from the
central mass after 7 days incubation (P < 0.05; Figure 2B).
When the cells were cultured in Matrigel™ in the pres-
ence of citicoline for 24 h, a significant increase in the
formation of tube-like structures was observed com-
pared with control cells (p < 0.01; Figure 2C). The in-
crease was higher than that observed with FGF-2 a
known potent angiogenic factor.
Citicoline increased the phosphorylation of phospho-ERK1/2
protein expression and novel proteins detected using a
phospho-protein kinexus western array in HCMEC/D3
Western blotting showed increased expression of
phospho-extracellular-signal regulated kinase (ERK1/2),
a key angiogenic mitogenic protein in hCMEC/D3 after
10 min stimulation with different concentrations of citi-
coline (Figure 3A). The screening Kinexus antibody
microarray performed by Kinexus on BAEC (Additional
Figure 2 Effects of citicoline on wound recovery, spheroid sprouting and tube-like structure formation in Matrigel. A) a significant
increase in the number of migrating cells from a scratch wound was seen in hCMEC 24 h after treatment with FGF-2 (positive control; ii) and
citicoline (10 μM; p = 0.015; iii). The bar chart represents the mean numbers of migrating cells from triplicate coverslips of control untreated cells,
FGF-2 positive control (25 ng/ml), and citicoline treated cells (10 μM). B) Shows that addition of citicoline (10 μM) significantly increased the
formation and intensity of spheroids as well as migration of cells outwards from the central mass after 7 days incubation (P = 0.005; iii). The bar
chart represents the mean sprout length of control spheroids after 7 days, FGF-2 (25 ng/ml), and Citicoline 10 μM. Values are expressed in μM
and at least 10 spheroids from each condition were analyzed. C) When cells were cultured in Matrigel™ in the presence of citicoline for 24 h, a
significant increase in the formation of tube-like structures was observed compared with control cells (p = 0.010; iii). The bar graphs and
photomicrographs shows control cells, cells treated with FGF-2 (25 ng/ml), cells treated with citicoline (10 μg/ml). The data illustrates the
significant increase in the numbers of closed-loop areas in the presence of citicoline (p = 0.010). Five areas from each well and 3 wells per
treatment were analyzed.
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the phosphorylation of ASK-1, HER2, IRS-1 and Jun and
an inhibition (<0.5 fold) for Hsp-70, Integrin alpha4,
MEK-1 and Histone H2B proteins (Figure 2; Additional
file 1: Figure S1). P-IRS-1 expression was increased in
citicoline-treated hCMEC/D3 (Figure 3B).
Since IRS-1 is known to be involved in promotion of
angiogenesis of vascular EC [12], we treated our
hCMEC/D3 with anti-sense siRNA directed against IRS-
1 and following down-regulation of protein expression,
observed a significant decrease (approximately 50%) in
tube-like-structure formation induced by citicoline alone
(Figure 3C), demonstrating that citicoline activatesangiogenesis at least partially through a pathway involv-
ing IRS-1.
Treatment with citicoline significantly increased the
numbers of an active (CD105-positive) microvessels in the
stroked region 21 days after the infarct
Treatment of rats with citicoline (1000 mg/Kg) intraper-
itoneally prior to reperfusion and daily until euthanasia
at day 21 post-infarct, resulted in a notable but not-
significant increase in CD31-positive and a significant
increase in CD105-positive (active) microvessels in the
peri-infarcted and infarcted regions, measured in eight
histologically processed serial sections from each rat at
Figure 3 Citicoline increased expression of p-ERK1/2 and p-IRS-1 in citicoline-treated hCMEC/D3, and treatment with anti-sense siRNA
directed against IRS-1 significantly inhibited tube-like structure formation. A and B) Representative Western blots showing the up-
regulation of ERK1/2 and IRS-1 phosphorylation after 10 min stimulation of hCMEC/D3 in basal-serum-poor medium. (i) Control cells showed little
p-ERK1/2/IRS-1 expression and (ii) after citicoline treatment (10 μM; 10 min) a notable increase was seen. Experiments were performed at least
twice and a representative example is shown together with a bar chart showing the fold increase in expression. C) hCMEC/D3 treated with anti-
sense siRNA directed against IRS-1, for 48 h prior to citicoline treatment (10 μM; 24 h), significantly reduced the ability of citicoline to induce
tube-like structure formation in matrigel. Data shown are the result of a single representative experiment performed in triplicate wells. The bar
graph illustrates the significant increase in the numbers of closed-loop areas in the presence of citicoline was reduced by approximately 50% in
the presence of siRNA to IRS-1 (p = 0.018). Five areas from each well and 3 wells per treatment were analyzed.
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areas at x 20 magnification) and compared with saline
treated controls (Figures 4, 5). Citicoline treatment had
no effect on the total infarct volume over this treatment
time.
IHC and Double immuno-fluorescent staining demonstrated
strong co-localization of CD105-positive neovessels in the
peri-infarcted region and p-IRS-1
IHC and Immunofluorescent labeling showed increased
expression of p-IRS-1 (Figure 6Ai and ii) and co-
localization of p-IRS-1 and CD105-positive microvesselsin the infarcted region of animals 21 days after the initial
MCAO and following citicoline treatment (Figure 6B).
Almost no staining was seen in control, untreated ani-
mals (data not included).
Discussion
In this study, we have, for the first time, demonstrated
both a vascular protective, and pro-angiogenic effect of
citicoline using in vivo and in vitro models. Here we show
the strong protective effect of citicoline on brain micro-
vascular EC, demonstrated by the ability of citicoline to
protect against either calcium ionophore or hypoxia-
Figure 4 Immunohistochemical staining for CD105 demonstrated the presence of significantly more active microvessels in stroke
regions of rats treated with citicoline following MCAO. Treatment with citicoline significantly increased the number of CD105-positive
microvessels in the peri-infarcted and infarcted regions following transient rat MCAO after 21 days. The figure shows citicoline-treated animals
(top row) versus saline treated controls (bottom row). Sections were immunohistochemically stained and developed using DAB (brown). Arrows
point to CD105-positively stained microvessels which were consistently more numerous in each animal studied following citicoline treatment
(n = 3; p = 0.021).
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take of propidium iodide. Previous studies have shown
that citicoline was able to protect motor neurons of orga-
notypic rat lumbar spinal cord cultures, from apoptosis
following administration of the excitotoxic agent DL-
threo-β-hydroxyaspartate (a glutamate analogue) [13].
Similarly, citicoline with or without hypothermia, pro-
tected neurons against apoptosis in a rat model of transi-
ent focal MCAO through a mechanism including the
modulation of Bcl-2, Bax and caspase-9 [14]. In other cell
types/sources, citicoline protected against cell damage
from Kainic acid in retinal neurons [15] and indirectly,
may protect lung adenocarcinoma cells (A549) against
apoptosis [16,17]. No studies until now have been carried
out using EC. Our data suggests a strong protective effect
against the damaging process of excitotoxicity and hyp-
oxia, similar to that experienced after acute ischaemic
stroke. In regard to the possible mechanism? Our kinexus
phospho-protein screen identified a tenfold reduction in
expression of Histone H2B (serine 14). Phosphorylation of
histone H2B at serine 14 (S14), a posttranslational modifi-
cation required for nuclear condensation, correlates with
cells undergoing programmed cell death in vertebrates
[18]. The authors of this paper also identified a 34 kDaapoptosis-induced H2B kinase as caspase-cleaved Mst1
(mammalian sterile twenty) kinase. Mst1 can phosphoryl-
ate H2B at S14 in vitro and in vivo, and the onset of H2B
S14 phosphorylation is dependent upon cleavage of Mst1
by caspase-3. These data reveal a histone modification that
is uniquely associated with apoptotic chromatin and pro-
vide insights into a previously unrecognized physiological
substrate for Mst1 kinase. Further experiments are needed
to confirm that these findings represent a key novel mech-
anistic pathway for EC protection associated with citico-
line treatment.
In addition, although citicoline had no effect on the
chemotaxis of HBMEC/D3 determined by using the Boy-
den chamber method it significantly increased the number
of migrating cells in the scratch wound healing assay. Citi-
coline also significantly increased the formation of tube-
like structure in Matrigel producing a stronger effect than
the known mitogenic factor FGF-2 (p <0.05). Although
citicoline had no mitogenic and chemotactic effects on
EC, it had a significant effect on cell differentiation and
migration which are two of the key steps of the angiogenic
process. This may be an extremely valuable novel finding
in regard to understanding the potential mechanisms
through which citicoline treatment results in patient
Figure 5 Immunohistochemical staining for CD31 demonstrated a trend for increased numbers of total microvessels in stroke regions
of rats treated with citicoline following MCAO. A) Treatment with citicoline increased the number of CD31-positive microvessels (total
number of vessels but did not reach significance) in the peri-infarcted and infarcted regions following transient rat MCAO after 21 days. The
figure shows citicoline-treated animals (top row) versus saline treated controls (bottom row). Sections were immunohistochemically stained and
developed using DAB (brown). Arrows point to CD31-positively stained microvessels which were morphologically more immature (thinner walls
and less pericyte coverage) present in larger numbers in each animal studied following citicoline treatment (n = 3). B) Bar chart showing the
increase in CD31 positive and CD105 positive vessels stained in sections (5 analyzed per animal) from rats following transient MCAO and
treatment with citicoline as described in the methods section (n = 3 in each group).
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maintenance of angiogenesis is key to both short-term
and chronic re-vascularization after stroke impacting in-
directly but significantly also on neuronal survival and re-
integration [19].
Western blotting demonstrated that citicoline induced
pERK1/2 expression, a key mitogenic signalling protein
known to be involved in angiogenesis and generally sti-
mulated by growth factors through interaction with their
receptors [20]. This data demonstrated the potential of
citicoline to activate intra-cellular signal transduction
pathways and induce phosphorylation of down-stream
angiogenic molecules; hence we investigated this abilityin more detail by analysis of the Kinexus-phospho-
protein Western screen following treatment of vascular
EC with citicoline. Interestingly, treatment with citico-
line modified the expression of only several of the >500
proteins on the array showing a degree of specificity.
IRS-1 and Her2 were both phosphorylated in the pres-
ence of citicoline. These two proteins have not been
implicated in stroke recovery pathways or stroke angio-
genesis until now.
Here, we went on to demonstrate the importance of
IRS-1 in mediating the angiogenic effects of citicoline
in vitro, and further showed localization of p-IRS-1 in
the vascular regions of peri-infarcted tissue of animals
Figure 6 Co-localization of CD105 (TRITC) and p-IRS-1 was seen in microvessels of citicoline-treated animals in stroke regions
following MCAO. Ai and ii) IHC staining of citicoline-treated rats (n = 5) demonstrated a notable increase in the staining of stroke-associated
microvessels with p-IRS-1 (DAB; brown). Representative staining is shown from one animal at magnifications of x 40 and x 100. Arrows represent
positively stained vessels. B) IF analysis demonstrated co-localization of CD105 (TRITC) and p-IRS-1 (FITC) in some of these vessels. In all
experiments, control sections were used where the primary antibody was replaced by PBS.
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citicoline. The vessels were nearly always thin-walled
neo-vessels with minimal or no pericyte coverage and
CD105-positive suggesting dynamic activity and contri-
bution to the re-vascularisation process.
Only recently, IRS-1 over-expression was attributed to
increased angiogenesis in human EC in association with
increased Akt and VEGF-A expression [12], whilst
in vivo, antisense IRS-1 sequences delivered by sub-
conjunctival injection inhibited rat corneal neovasculari-
sation [21], and when delivered by means of eye-drops
(GS-101) were found to be tolerable in a phase-1 clinical
trial and may be sufficient to prevent neovascularisation
in disease such as retinopathy and neovascular glaucoma
[22]. Therefore, IRS-1 represents a potent modulator of
pro-angiogenic signalling cascades in vascular EC and as
such, since we have shown both in vitro, and in the rat
model of temporary MCAO that citicoline induces phos-
phorylation of IRS-1 and concomitant EC activation and
increased vascularisation, this could be a key novel
mechanism of action of citicoline.A further interesting finding was the up-regulation of
HER2 by citicoline in our vascular ECs in vitro. Al-
though we have not investigated this in more detail
within this piece of work or in our hCMEC, HER2 has
previously been shown to be important in promotion of
angiogenesis and concomitant tumour breast tumour
growth [23], and is strongly implicated in activation of
intracellular signalling pathways increasing the expres-
sion of VEGF and IL-8 [24]. Therefore, further investiga-
tion is warranted to determine its importance in the
induction of citicoline-associated angiogenesis and vas-
cularisation after ischaemic stroke.
Conclusion
In conclusion, citicoline induces angiogenesis and
improves survival of human brain microvessel endothelial
cells through pathways involving p-ERK1/2, and IRS-1
and it is probable that other novel signalling intermediates
are also involved including Histone H2B and HER2 (more
studies are needed to confirm this) and therefore following
chronic treatment, its beneficial effects after stroke may in
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http://www.vascularcell.com/content/4/1/20part be due to revascularization. Based on our findings,
optimization of its therapeutic use to include vascular
tissue regeneration should be re-considered.
Additional file
Additional file 1: Figure S1. Kinexus bar chart.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
JK, MS and JS designed the experimental protocols/project management
and drafted the manuscript; MA, SM and DL performed the experimental
work in vitro; CA and JP performed the in vivo studies; RA, NR, MG and EP
helped to design the study and prepare the manuscript. All authors read
and approved the final manuscript.
Disclosures
Authors have no additional disclosures.
Sources of funding
This study was supported from research grant from Ferrer International.
Author details
1Cerebrovascular Diseases, Department of Neurology, Hospital Universitari
Mútua Terrassa, Terrassa, Barcelona, Spain. 2Department of Medicine,
University of Manchester, Manchester, UK. 3School of Healthcare Science,
Manchester Metropolitan University, Manchester, UK. 4College of Applied
Medical Science, Almajmaáh University, P.O. Box 1405, Almajmaah 11952,
Kingdom of Saudi Arabia. 5School of Medicine, Centre for Medicine and Oral
Health campus, Gold Coast Campus, Griffith University, Queensland, QLD
4222, Australia. 6Department of Brain Ischemia and Neurodegeneration,
IIBB-CSIC, IDIBAPS, Rossello 161, Barcelona E-08036, Spain. 7Cardiovascular
Research Center, Hospital de Sant Pau and IIB-Sant Pau, CiberOBN-Instituto
de Salud Carlos III, Barcelona, Spain. 8Ferrer Grupo, Barcelona, Spain.
Received: 10 September 2012 Accepted: 27 November 2012
Published: 10 December 2012
References
1. Secades JJ: Probably role of citicoline in stroke rehabilitation: review of
the literature. Rev Neurol 2012, 54(3):173–179.
2. Blount PJ, Nguyen CD, McDeavitt JT: Clinical use of cholinomimetic
agents: a review. J Head Trauma Rehabil 2002, 17:314–321.
3. Hurtado O, Cárdenas A, Pradillo JM, Morales JR, Ortego F, Sobrino T, et al:
A chronic treatmente with CDP-choline improves functional recovery
and increases neuronal plasticity after experimental stroke. Neurobiol Dis
2007, 26:105–111.
4. Davalos A, Secades J: Citicoline preclinical and clinical update 2009–2010.
Stroke 2011, 42:S36–S39.
5. Lee HJ, Kang JS, Kim YI: Citicoline protects against cognitive impairment
in a rat model of chronic cerebral hypoperfusion. J Clin Neurol 2009,
5:33–38.
6. Giralt D, Garcia-Bonilla L, Campos M, Sosti V, Rosell A, Montaner J: Selecting
the optimal dose of citicoline treatment in animal models of focal
cerebral ischaemia through a meta-analysis. Cerebrovasc Dis 2010, 29:165.
7. Saver JL: Citicoline: updata on a promising and widely available agent for
neuroprotection and neurorepair. Rev Neurol Dis 2008, 5:167–177.
8. Krupinski J, Ferrer I, Barrachina M, Secades JJ, Mercadal J, Lozano R: CDP-
choline reduces pro-caspase and cleaved caspase-3 expression, nuclear
DNA fragmentation, and specific PARP-cleaved products of caspase
activation following middle cerebral artery occlusion in the rat.
Neuropharmacology 2002, 42:846–854.
9. Weksler BB, Subileau EA, Perriere N, Charneau P, Holloway K, Leveque M,
et al: Blood–brain barrier-specific properties of a human adult brain
endothelial cell line. FASEB J 2005, 19:1872–1874.10. Slevin M, Matou-Nasri S, Turu M, Luque A, Rovira N, Badimon L, et al:
Modified C-reactive protein is expressed by stroke neovessels and is a
potent activator of angiogenesis in vitro. Brain Pathol 2010, 20:151–165.
11. Longa EZ, Weinstein PR, Carlson S, Cummins R: Reversible middle cerebral
artery occlusion without craniectomy in rats. Stroke 1989, 20:84–91.
12. Al-Mahmood S, Colin S, Farhat N, Thorin E, Steverlynck C,
Chemtob S: Potent in vivo antiangiogenic effects of GS-101
(50-TATCCGGAGGGCTCGCCATGCTGCT-30) an antisense oligonucleotide
preventing the expression of insulin receptor substrate-1. J Pharmacol
Exp Ther 2009, 329:496–504.
13. Matyja E, Taraszewska A, Naganska E, Grieb P, Rafalowska J: CDP-choline
protects motor neurons against apoptotic changes in a model of
chronic glutamate excitotoxicity in vitro. Folia Neuropathol 2008,
46:139–148.
14. Sahin S, Alkran T, Temel SG, Tureyen K, Tolunay S, Korfali E: Effects of
citicoline used alone and in combination with mild hypothermia on
apoptosis induced by focal cerebral ischaemia in rats. J Clin Neurosci
2010, 17:227–231.
15. Han YS, Chung IY, Park JM, Yu JM: Neuroprotective effect of citicoline on
retinal cell damage induced by kainic acid in rats. Korean J Ophthalmol
2005, 19:219–226.
16. Joo JH, Jetten AM: Molecular mechanisms involved in farnesol-induced
apoptosis. Cancer Lett 2010, 287:123–135.
17. Miquel K, Pradines A, Terce F, Selmi S, Favre G: Competetive inhibition of
choline phosphotransferase by geranylgeraniol and farnesol inhibits
phosphatidylcholine synthesis and induces apoptosis in human lung
adenocarcinoma A549 cells. J Biol Chem 1998, 273:26179–26186.
18. Cheung WL, Ajiro K, Samejima K, Kloc M, Cheung P, Mizzen CA, et al:
Apoptotic phosphorylation of histone H2B by mammalian sterile twenty
kinase. Cell 2003, 113:507–517.
19. Mitsios N, Gaffney J, Kumar P, Krupinski J, Kumar S, Slevin M:
Pathophysiology of acute ischaemic stroke: an analysis of common
signalling mechanisms and identification of new molecular targets.
Pathobiol 2006, 73:159–175.
20. Slevin M, Kumar P, Gaffney J, Kumar S, Krupinski J: Can angiogenesis be
exploited to improve stroke outcome? Mechanisms and therapeutic
potential. Clin Sci 2006, 111:171–183.
21. Andrieu-Soler C, Berdugo M, Doat M, Courtois Y, BenEzra D, Behar-Cohen E:
Down-regulation of IRS-1 expression causes inhibition of corneal
angiogenesis. Invest Ophthalmol Vis Sci 2005, 46:4072–4078.
22. Kain H, Goldblum D, Geudelin B, Thorin E, Beglinger C: Tolerability and
safety of GS-101 eye drops, an antisense oligonucleotide to insulin
receptor substrate-1: a first in man phase 1 investigation. Br J Clin
Pharmacol 2009, 68:169–173.
23. Foy KC, Liu Z, Phillips G, Miller M, Kaumaya PT: Combination treatment
with HER-2 and VEGF peptide mimics induces potent anti-tumour and
anti-angiogenic responses in vitro and in vivo. J Biol Chem 2011,
286:13626–13637.
24. Wen XF, Yang G, Mao W, Thornton A, Liu J, Bast RC Jr, Le XF: HER2
signaling modulates the equilibrium between pro-and antiangiogenic
factors via distinct pathways: implications for HER2 –targeted antibody
therapy. Oncogene 2006, 25:6986–6996.
doi:10.1186/2045-824X-4-20
Cite this article as: Krupinski et al.: Citicoline induces angiogenesis
improving survival of vascular/human brain microvessel endothelial
cells through pathways involving ERK1/2 and insulin receptor
substrate-1. Vascular Cell 2012 4:20.
